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ABSTRACT
Objective In newly diagnosed paediatric patients with 
moderate- to- severe Crohn’s disease (CD), infliximab 
(IFX) is initiated once exclusive enteral nutrition (EEN), 
corticosteroid and immunomodulator therapies have 
failed. We aimed to investigate whether starting first- line 
IFX (FL- IFX) is more effective to achieve and maintain 
remission than conventional treatment.
Design In this multicentre open- label randomised 
controlled trial, untreated patients with a new 
diagnosis of CD (3–17 years old, weighted Paediatric 
CD Activity Index score (wPCDAI) >40) were assigned 
to groups that received five infusions of 5 mg/kg 
IFX at weeks 0, 2, 6, 14 and 22 (FL- IFX), or EEN 
or oral prednisolone (1 mg/kg, maximum 40 mg) 
(conventional). The primary outcome was clinical 
remission on azathioprine, defined as a wPCDAI <12.5 
at week 52, without need for treatment escalation, 
using intention- to- treat analysis.
Results 100 patients were included, 50 in the FL- IFX 
group and 50 in the conventional group. Four patients 
did not receive treatment as per protocol. At week 10, 
a higher proportion of patients in the FL- IFX group than 
in the conventional group achieved clinical (59% vs 
34%, respectively, p=0.021) and endoscopic remission 
(59% vs 17%, respectively, p=0.001). At week 52, 
the proportion of patients in clinical remission was not 
significantly different (p=0.421). However, 19/46 (41%) 
patients in the FL- IFX group were in clinical remission on 
azathioprine monotherapy without need for treatment 
escalation vs 7/48 (15%) in the conventional group 
(p=0.004).
Conclusions FL- IFX was superior to conventional 
treatment in achieving short- term clinical and endoscopic 
remission, and had greater likelihood of maintaining 
clinical remission at week 52 on azathioprine 
monotherapy.
Trial registration number  ClinicalTrials. gov Registry 
(NCT02517684).
INTRODUCTION
In newly diagnosed paediatric patients with 
Crohn’s disease (CD), rapid disease control is 
desirable, but this outcome is not always achieved 
Significance of this study
What is already known on this subject?
 ► Crohn’s disease is an incurable, debilitating IBD 
that presents during childhood or adolescence 
in 8% of all patients with Crohn’s disease.
 ► In adult patients with Crohn’s disease, early 
infliximab (IFX) treatment has shown to 
affect the natural course of the disease, 
with a decrease in the occurrence of disease 
complications.
 ► Although corticosteroids are known to 
negatively impact growth and development 
in children and adolescents, IFX is 
currently reserved for corticosteroid and 
immunomodulator refractory paediatric Crohn’s 
disease.
What are the new findings?
 ► Ten weeks after start of therapy, the proportion 
of children in clinical and endoscopic remission 
is significantly higher in the group treated with 
first- line IFX than in the group that received 
exclusive enteral nutrition or prednisolone 
(conventional treatment).
 ► First- line IFX treatment is superior in achieving 
clinical remission on azathioprine monotherapy 
at 1 year without the need for corticosteroids 
or further biologics. A significant proportion of 
children in the conventional treatment group 
received an additional course of corticosteroids.
 ► Despite the possibility to escalate to treatment 
with IFX, the group that received conventional 
treatment shows poorer growth at 1 year.
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with current treatment strategies. The European Society 
of Paediatric Gastroenterology, Hepatology and Nutrition 
consensus guideline recommends starting with exclusive 
enteral nutrition (EEN) or oral corticosteroids for induction of 
remission in conjunction with immunomodulator maintenance 
treatment. Infliximab (IFX), an anti- tumour necrosis factor 
alpha (TNF-α) agent, is increasingly being used in paediatric 
patients with CD refractory to steroids and/or immunomod-
ulators and results in high- sustained remission rates.1 IFX is 
started if response to the conventional treatment strategy case 
is inadequate.2
In many paediatric patients with CD, however, particularly 
in those with moderate- to- severe CD, mucosal healing and 
sustained clinical remission are not achieved with conventional 
treatment.3 First- line IFX (FL- IFX) is mentioned in the current 
paediatric CD treatment guidelines as the preferred strategy only 
for patients with CD with active perianal fistulising disease and 
those at risk of disabling disease.2 4 It has already been suggested 
by several observational studies, however, that primary IFX 
therapy may be very effective in inducing and maintaining 
clinical remission in paediatric patients with luminal CD.5–7 A 
randomised controlled trial (RCT) in adult patients with CD 
who had recently been diagnosed showed that early treatment 
with IFX in combination with immunomodulators was more 
effective than conventional treatment with corticosteroids, but 
an RCT in therapy- naïve patients has not been performed.8 As 
paediatric- onset CD often presents with a more severe pheno-
type of disease than adult- onset CD,9 this suggests that paedi-
atric patients with CD may benefit even more from an FL- IFX 
strategy by preventing accumulating damage due to chronic 
uncontrolled inflammation.10 If mucosal healing can be achieved 
by establishing early control of inflammation, sustained clinical 
remission will be attained and development of complications 
such as strictures and perforations may be prevented in these 
paediatric patients.
We hypothesise that induction of remission with FL- IFX in 
moderate- to- severe paediatric patients with CD results in higher 
early clinical and endoscopic remission rates, and superior rate 
of clinical remission maintenance on azathioprine (AZA) mono-
therapy compared with conventional treatment. Therefore, we 
aim to compare the efficacy of FL- IFX treatment with conven-
tional treatment in newly diagnosed patients with moderate- to- 
severe paediatric CD.
METHODS
Study design and participants
We designed an investigator- initiated international open- label 
RCT in adherence to the Consolidated Standards of Reporting 
Trials statement. The trial was performed in 12 hospitals in three 
European countries (the Netherlands, Croatia and Finland). The 
study protocol was published.11 Inclusion and exclusion criteria are 
defined in table 1.
It was aspired to enrol patients as soon as possible following 
diagnostic endoscopy. After CD diagnosis had been established 
and eligibility criteria had been met, written informed consent was 
obtained from the patient (if ≥12 years) and both parents and/or 
guardians.
Randomisation and masking
Included patients were stratified by centre and equally 
randomised into two treatment groups with a validated vari-
able block randomisation model, incorporated in the web- based 
database used for this trial (Castor Electronic Data Capture).12 
Allocation was concealed for all participants and healthcare 
providers. Participants were randomly assigned to the experi-
mental FL- IFX group or to the control group, referred to as the 
conventional treatment group. Participants, investigators and 
healthcare providers were not masked to treatment allocation.
Procedures
The FL- IFX group received five intravenous IFX (Inflectra, CT- P13) 
infusions of 5 mg/kg induction at weeks 0, 2 and 6, followed by 
two maintenance infusions every 8 weeks. This was combined with 
oral AZA as maintenance treatment (once daily, dosed 2–3 mg/kg), 
which was initiated on the day induction treatment was started 
(figure 1). Conventional treatment consisted of standard induction 
treatment with either EEN (polymeric feeding for 6–8 weeks, after 
which normal diet was gradually reintroduced within 2–3 weeks) or 
oral prednisolone (for 4 weeks 1 mg/kg daily with a maximum of 
40 mg, followed by tapering down to 5 mg per week until stop).2 
Whether patients received induction treatment with EEN or pred-
nisolone was based on patient preference, in accordance with the 
treating physician. Patients and parents were informed about all 
treatment options prior to randomisation. The choice between EEN 
and prednisolone was made after being assigned to the conven-
tional treatment group. Similar to the FL- IFX group, both EEN and 
prednisolone were combined with oral AZA as maintenance treat-
ment (2–3 mg/kg, once daily) in the conventional treatment group. 
AZA dosing was halved in case of thiopurine methyl transferase 
Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Patient is 3–17 years of age Indication for primary surgery
Patient presents with new- 
onset untreated CD according 
to the revised Porto criteria34
Symptomatic stenosis or stricture in the bowel due 
to scarring
wPCDAI >40 at baseline Active perianal fistulas
Body weight >10 kg at 
baseline
Presence of a serious comorbidity, such as 
infection, sepsis, opportunistic infection, positive 
stool culture (Salmonella enterica, Shigella spp, 
Yersinia enterocolitica or Campylobacter spp), 
positive Clostridium difficile toxin assay or positive 
tuberculosis screening
Presentation with suspected or definite pregnancy
Already using CD- specific therapy
CD, Crohn’s disease; wPCDAI, weighted Paediatric Crohn’s Disease Activity Index.
Significance of this study
How might it impact on clinical practice in the foreseeable 
future?
 ► This study, being the first randomised controlled trial that 
investigates the effectiveness of first- line IFX in therapy- naïve 
paediatric patients with Crohn’s disease, argues that children 
with moderate- to- severe Crohn’s disease would benefit from 
first- line IFX treatment.
 ► Considering the detrimental impact of an insufficiently 
effective treatment strategy on growth, development and 
school attendance of these children and adolescents, a 
maximally effective therapy from diagnosis onwards is highly 
desired. This study provides evidence for starting IFX therapy 
in children with newly diagnosed moderate- to- severe Crohn’s 
disease.
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(TPMT) heterozygosity. As part of clinical care, AZA metabolites 
(6- thioguanine nucleotides and 6- methylmercaptopurine) were 
measured around the time of induction treatment cessation, and 
complete blood counts were performed weekly in the first month, 
monthly in the second and third months, and thereafter once every 
3 months (online supplemental table 1). In both groups, metho-
trexate was the second choice immunomodulator, only prescribed 
in the event of low or absent TPMT activity or side effects of AZA.
In both groups, data were collected prior to start of induction 
therapy, at weeks 6, 10, 14, 22 and 52. At each visit, weighted Paedi-
atric Crohn’s Disease Activity Index (wPCDAI) was determined,13 
blood was obtained for routine laboratory analysis and serum 
samples were collected (in conventionally treated patients at start, 
week 10 and week 52). SD scores (SDS) adjusted for sex and age 
were used to evaluate linear growth. The height- for- age SDS were 
calculated with the Growth Analyser Research Calculation Tool, 
based on the Dutch national reference standards for all patients 
included in the Netherlands and the WHO growth reference stan-
dards for all patients included in other countries.14 Target height and 
target height SDS were calculated.15 Endoscopy (ileocolonoscopy) 
was performed prior to start of treatment, at week 10, and option-
ally at week 52. During endoscopy, the Simple Endoscopic Score for 
Crohn’s Disease (SES- CD) was used to evaluate endoscopic remis-
sion,16 which was defined as a SES- CD score <3. A single reader, 
blinded for both assigned treatment and time point, evaluated and 
rescored all endoscopic still images available by using the physician 
global assessment endoscopy score,17 to check interobserver vari-
ability between paediatric gastroenterologists (r=0.661, p>0.001). 
The SES- CD score was used for analyses regarding endoscopic 
findings. Faecal samples were collected for faecal calprotectin level 
measurement prior to start of treatment, at week 10 and at week 
52. Faecal calprotectin levels were assessed in the Erasmus Medical 
Centre with ELISA (CALPRO assay). When faecal samples were 
missing, faecal calprotectin levels determined in the local hospital at 
this time point were used, which accounted for 15% of all samples. 
A faecal calprotectin level <100 µg/g was defined as biochemical 
remission.18 In patients ≥9 years old, quality of life (QOL) was 
assessed with the validated IMPACT III questionnaire. Scores range 
from 0 to 100, with a higher score indicating a better QOL.19
In case of non- response or absence of response (response being 
a decrease in wPCDAI of >17.5 points), the treatment advice for 
FL- IFX- treated patients was to shorten the IFX dosing interval to 
6 weeks and/or to double the dose to 10 mg/kg. In accordance 
with clinical practice, clinicians could perform reactive therapeutic 
drug monitoring (TDM) to guide this decision. Initiation of IFX 
treatment was advised for conventionally treated patients. To 
guide clinical decision- making for treatment escalation, secondary 
loss of response was defined either by an increase of the wPCDAI 
with >17.5 points or by a total wPCDAI score >40 after response 
had been achieved. If FL- IFX- treated patients were not in clinical 
remission at week 22, it was recommended to continue the IFX 
infusions as standard care, instead of stopping after five infusions. 
Patients requiring such extended IFX therapy were considered 
treatment failures in intent- to- treat analysis of outcomes following 
five doses of FL- IFX. If FL- IFX- treated patients had loss of response 
during AZA monotherapy, it was advised to check AZA metab-
olite levels to assess optimal treatment. Contingent on optimal 
AZA metabolite levels, it was advised to restart IFX maintenance 
therapy every 8 weeks, also meaning treatment failure. Conven-
tionally treated patients with loss of response during AZA mono-
therapy were advised to step up to IFX therapy after checking AZA 
metabolites and optimising its dosing in case of suboptimal levels. 
In addition to these guidelines, in patients without response, loss of 
response or intolerance to treatment, changes in treatment could 
be made according to the physician’s discretion.
Outcomes
Primary outcome
The primary outcome of this study was clinical remission, 
defined as wPCDAI <12.5 at week 52, without need for treat-
ment escalation. Any additional CD- related therapy or surgery 
during the 52 weeks was considered treatment escalation.
Definition of treatment escalation
Additional CD- related therapy in the FL- IFX group included 
(1) any course of corticosteroids, (2) increase of the IFX dose, 
(3) shortening of the IFX treatment interval, (4) continuation 
or restart of IFX after the standard five infusions, or (5) start 
of another biological agent. Additional CD- related therapy in 
the conventional treatment group included initiation of IFX and 
any course of corticosteroids that was additional to the standard 
treatment described in the previous section.
Secondary outcomes
Secondary outcomes included time- to- treatment escalation from 
start of induction and clinical disease activity scores over time. 
At week 10, clinical remission rate, endoscopic remission rate 
and faecal calprotectin level were assessed. QOL was evaluated 
at week 14. At week 52, the following outcomes were assessed: 
(1) additional corticosteroid use, (2) need for treatment esca-
lation, (3) linear growth, (4) clinical remission rate, (5) endo-
scopic remission rate, (6) faecal calprotectin level, (7) QOL and 
(8) rate of adverse events. An adverse event was defined as any 
undesirable experience occurring to a subject during the study, 
whether or not it was considered to be related to the investiga-
tional product or the experimental treatment.
Statistical analysis
Based on published studies reporting effectiveness of FL- IFX 
treatment and early IFX use6 in paediatric patients with CD, a 
Figure 1 Trial design. Illustration of treatment procedures in this trial. EEN, exclusive enteral nutrition; IFX, infliximab.
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power calculation was performed.7 20 Based on these studies a 
clinical remission rate of 60% in conventionally treated patients 
and 85% in FL- IFX- treated patients was expected. One- hundred 
patients (50 in each arm, considering a drop- out rate of 2%) 
were required to find this 25% difference in clinical remission 
at week 52 with a power of 80% (two- sided α 0.05).11 Data 
were analysed on an intention- to- treat basis. Safety analyses 
were based on the actual treatment patients received (ie, per 
protocol). Continuous variables were presented as medians and 
IQRs, and compared with the Mann- Whitney U test. Categorical 
variables were presented as absolute frequencies and percent-
ages and compared by the X2 test or the Fisher exact test. The 
Wilcoxon signed rank test was used to compare height- for- age 
SDS at different time points within one treatment group. SES- CD 
scores with a missing ileum subscore due to the endoscopist’s 
failure to intubate the terminal ileum were included in the anal-
ysis to evaluate endoscopic remission. The median faecal calpro-
tectin levels and SES- CD scores were subject to right censoring. 
To correct for this, medians of faecal calprotectin levels and 
SES- CD scores were calculated using the Kaplan- Meier method, 
and treatment groups for these outcomes were compared using 
the log- rank test. The multiple imputation method was used for 
missing erythrocyte sedimentation rate (ESR) levels (14.8%), 
missing albumin levels (10.5%) and missing faecal calprotectin 
levels (10.9%) in order to calculate biochemical remission rate. 
Twenty complete datasets were created for multiple imputation. 
For the primary outcome, no imputation was performed as <5% 
of data were missing. The time- to- treatment escalation outcomes 
were analysed using the Kaplan- Meier method. A paired analysis 
was performed for the linear growth. The mean clinical disease 
activity score over time was calculated with a linear mixed model, 
including the assigned treatment as a fixed effect and intercept 
as random effect. Random slopes were tested but not included.
All analyses were performed based on a significance level of 0.05. 
Calculations were performed using IBM SPSS Statistics V.24.0.
RESULTS
Patients were recruited between 7 April 2015 and 19 November 
2018. A total of 195 patients were screened for eligibility in this 
trial. One hundred patients were randomly assigned to FL- IFX 
(n=50) or conventional treatment (n=50) (figure 2). One patient 
in the conventional treatment group did not receive the study treat-
ment she had been assigned to. Based on ethical considerations, 
she received the same (FL- IFX) treatment as her monozygotic twin 
sister, who had been included in this study previously. Two patients 
declined participation after randomisation, prior to the start of 
treatment. In the FL- IFX group, one patient was initially misclassi-
fied as CD, and this diagnosis was adjusted to ulcerative colitisat a 
later stage of the study. This patient, therefore, was excluded from 
all analyses. Patient and disease characteristics at baseline were 
similar between treatment groups (table 2).
The median time between diagnostic endoscopy and start of 
treatment for all included patients was 8 days (IQR 4–14). Twenty- 
seven patients (56%) in the conventional treatment group received 
EEN as primary induction therapy, while 20 patients (42%) received 
prednisolone (online supplemental table 2A).
Efficacy of induction therapy
Ten weeks after start of induction therapy, significantly more 
FL- IFX- treated patients than conventionally treated patients 
were in clinical remission (59% (24/41) vs 34% (15/44), 
p=0.021). Fifty- seven patients (27 FL- IFX and 30 conven-
tional), with similar baseline characteristics (online supple-
mental table 2B), underwent endoscopy at week 10. A higher 
proportion of patients in the FL- IFX group achieved endoscopic 
remission (16/27 (59%) vs 5/30 (17%), p=0.001, table 3) and 
median SES- CD scores were lower in the FL- IFX group (3 (IQR 
0–5) vs 9 (IQR 3–19), p=0.005). In addition, the proportion of 
patients with a faecal calprotectin level <100 µg/g was higher in 
the FL- IFX group, and C reactive protein, ESR and leucocyte 
levels were lower (table 3).
Treatment course
The mean wPCDAI score at all time points, corrected for 
repeated measurements, was lower in the FL- IFX group than 
in the conventional treatment group, although not significantly 
different (9.8 vs 14.2, respectively, p=0.07) (online supple-
mental figure 1). During the 52 weeks of follow- up, 43% of 
patients (95% CI 30% to 57%) in the FL- IFX group and 75% 
of patients (95% CI 60% to 86%) in the conventional treat-
ment group needed treatment escalation (p=0.001, figure 3A). 
Disease activity scores and level of inflammatory markers at 10 
and 14 weeks after induction treatment were higher in those 
who received treatment escalation than in those who did not 
(online supplemental table 3).
Assessed for eligibility (n=195)
Excluded (n=95)
• Not meeting inclusion criteria (n=62)
• Declined to participate (n=21)
• Unknown (n=3)
Allocated to FL-IFX group (n=50)
• Received allocated intervention (n=50)
Discontinued intervention (n=1)
• Diagnosis UC (n=1)
Analysed in FL-IFX group (n=49)
Allocated to conventional treatment group (n=50)
• Received allocated intervention (n=47)
• Did not receive allocated intervention (n=3)
- Received FL-IFX treatment (n=1)
- Consent withdrawal after randomisation (n=2)






















Figure 2 Trial profile. Flow chart of screened, randomised and treated patients. FL- IFX, first- line infliximab treatment.
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FL-IFX treatment
Twenty- one patients in the FL- IFX group needed treatment 
escalation. Twelve (24.5%) continued IFX therapy after the five 
per- protocol infusions (table 4A and figure 3B). Twenty- eight 
patients did not need treatment escalation.
Based on reactive TDM 2/49 patients received dose escala-
tion within the first 22 weeks. None of the seven patients that 
restarted IFX experienced side effects or needed to stop within 
the first year of follow- up.
Conventional treatment
As depicted in figure 3B, 40% of conventionally treated patients 
were already escalated to a second course of corticosteroids 
(19%) or IFX (21%) at week 14. Twenty patients received one 
or more courses of corticosteroids on top of the per- protocol 
use within the first year (table 4B). This resulted in extra corti-
costeroid use for a median duration of 67 days (IQR 53.3–72.3) 
in these patients. None of the patients received an extra EEN 
course. Thirty- six patients in the conventional treatment group 
needed treatment escalation.
Table 2 Baseline characteristics per treatment group
FL- IFX (n=49) Conventional (n=50)
Age at diagnosis (years) 15.1 (11.9–16.6) 14.1 (11.3–16.1)
Male sex (n) 24 (49.0%) 27 (54.0%)
Height (cm) 166 (154–175) 161 (143–170)
Height- for- age (SDS) −0.07 (−0.84 to 0.76) −0.53 (−1.06 to 0.26)
Weight (kg) 47.3 (36.8–57.1) 44.7 (30.3–55.0)
Tanner stage 4 (2–5)* 3 (1–4)*
wPCDAI 57.5 (47.5–67.5) 57.5 (47.5–73.8)
CRP (mg/L) 32.0 (11.5–46.5) 38.0 (22.0–65.9)
ESR (mm/hour) 35.0 (26.0–47.5) 32.0 (21.5–52.0)†
SES- CD 18.0 (11–26)† 18.0 (9–23)
Leucocytes (109/L) 8.2 (7.3–10.7) 9.1 (6.8–11.9)
Faecal calprotectin (µg/g) 1114 (763–1869) 1086 (592–1661)
Perianal disease‡ 5 (10%) 9 (18%)
Paris classification
  Age at diagnosis (years)
  <10 4 (8%) 9 (18%)
  10–17 39 (80%) 37 (74%)
  17–40 6 (12%) 4 (8%)
  Disease location
  L1 12 (25%) 11 (22%)
  L2 11 (22%) 12 (24%)
  L3 25 (51%) 27 (54%)
  Isolated L4 1 (2%) –
  Upper disease location
  No upper GI 29 (59%) 25 (50%)
  L4a 19 (39%) 21 (42%)
  L4b 1 (2%) 4 (8%)
  Disease behaviour
  B1 46 (94%) 43 (86%)
  B2 3 (6%) 7 (14%)
  B3 – –
  B2B3 – –
Growth delay 0 (0%)† 2 (4%)
Time between diagnostic endoscopy and start of treatment (days) 9 (5–14) 7 (2–14)
Data are presented as n (%) or median (IQR).
Baseline characteristics were not significantly different between treatment groups.
*>1 missing data point.
†One missing data point.
‡Perianal disease comprised inactive fistula, skin tags or anal fissures.
CRP, C reactive protein; ESR, erythrocyte sedimentation rate; FL- IFX, first- line infliximab; SDS, SD score; SES- CD, Simple Endoscopic Score for Crohn’s Disease; wPCDAI, weighted 
Paediatric Crohn’s Disease Activity Index.
Table 3 Findings at 10 weeks after start of induction therapy in the 
first- line IFX group versus the conventional treatment group
First- line IFX Conventional P value
Fcal (µg/g), median (IQR) 286 (62–596) 545 (279–1108) 0.004
Patients with Fcal <100 µg/g, 
n (%)
13/39 (33) 5/38 (13) 0.036
CRP (mg/L), median (IQR) 2.0 (0.8–3.2) 8.4 (2.0–23.8) <0.001
ESR (mm/hour), median (IQR) 6.5 (3.0–17.3) 17 (8.0–33.0) 0.003
Total leucocyte count (109/L), 
median (IQR)
5.5 (4.8–7.1) 7.3 (5.9–9.3) 0.001
CRP, C reactive protein; ESR, erythrocyte sedimentation rate; Fcal, faecal 
calprotectin; IFX, infliximab.
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Findings after 1-year follow-up
At week 52, the primary outcome of clinical remission without 
need for treatment escalation was reached in more FL- IFX- 
treated patients than in conventionally treated patients. In partic-
ular, 19/46 (41%) of the FL- IFX- treated patients were in clinical 
remission without need for treatment escalation, vs 7/48 (15%) 
of the conventionally treated patients (figure 4). This resulted in 
a 26% absolute difference (95% CI 0.18% to 0.35%, p=0.004). 
Irrespective of any treatment escalation during the study period, 
no significant differences were found in clinical, biochemical and 
endoscopic remission at week 52 (table 5).
In contrast, in the FL- IFX- treated patients median SDS height- 
for- age significantly improved between baseline and week 52 
(median SDS of −0.07 (IQR −0.84 to 0.76) at baseline vs 0.02 
(IQR −0.81 to 0.70) at week 52, p=0.045), while it significantly 
decreased in conventionally treated patients (median SDS of 
−0.53 (IQR −1.06 to 0.26) at baseline vs −0.66 (IQR −1.13 to 
0.11) at week 52, p=0.020) (table 6).
Quality of life
At week 14 and week 52, the median QOL scores in the FL- IFX 
group and conventional group were similar and in both groups 
significantly higher at both time points than at baseline (online 
supplemental table 4). The median QOL score in the FL- IFX group 
increased from 59.3 at baseline (IQR 48.2–71.8) to 79.7 at week 
52 (IQR 70.9–88.5, p<0.001) and in the conventional group from 
61.2 (IQR 49.8–70.7) to 77.5 (IQR 66.3–85.0, p<0.001).
Safety
There was no significant difference between the proportion 
of patients with an adverse event in the FL- IFX group (44%) 
versus the conventional treatment group (60%; absolute differ-
ence of 16%; 95% CI: −0.04% to 0.33%, p=0.125). In total, 94 
adverse events occurred, 40 of which were reported in FL- IFX- 
treated patients and 54 in conventionally treated patients. Fifteen 
serious adverse events were reported (table 7).
Figure 3 Proportion of patients who needed treatment escalation. 
(A) Kaplan- Meier estimates of the time- to- treatment escalation after 
start of therapy. Any additional CD- related therapy or surgery during the 
52 weeks was considered treatment escalation. Additional CD- related 
therapy in the FL- IFX group included: (1) any course of corticosteroids, 
(2) increase of the IFX dose, (3) shortening of the IFX treatment interval, 
(4) continuation or restart of IFX after the standard five infusions or (5) 
start of another biological agent. In the conventional treatment group, 
additional CD- related therapy included start of IFX and any course 
of corticosteroids that was additional to the standard treatment. (B) 
Proportion of patients receiving each treatment option from 10 weeks 
onwards, depicted per randomised group. AZA, azathioprine; CD, Crohn’s 
disease; CS, corticosteroid; FL- IFX, first- line infliximab.
Table 4A Type of treatment escalation in the FL- IFX treatment group 
within 52 weeks
Number of patients needing treatment escalation in the FL- IFX group, per- 
treatment escalation type
Continuation of IFX after five infusions; n (%) 12/49 (24.5)
Restart anti- TNF therapy; n (%) 7/49 (14.5)
  Infliximab; n 6
  Adalimumab; n 1
Corticosteroid course; n (%) 2/49 (4)
FL- IFX, first- line infliximab; TNF, tumour necrosis factor.
Table 4B Type of treatment escalation in the conventional treatment 
group
Number of patients needing treatment escalation in the conventional group, 
per- treatment escalation type
Intensification to IFX; n (%) 16/48 (33)
Additional corticosteroids followed by IFX; n (%) 13/48 (27)
One or more courses of corticosteroids; n (%) 7/48 (15)
IFX, infliximab.
Figure 4 Proportion of patients in clinical remission without 
treatment escalation. The proportion of patients in clinical remission, 
defined as a weighted Paediatric Crohn’s Disease Activity Index <12.5, 
without treatment escalation at 52 weeks after the start of induction 
therapy. CS, corticosteroid; EEN, exclusive enteral nutrition; FL- IFX, first- 
line infliximab.
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DISCUSSION
This is the first RCT to compare the efficacy of IFX directly after 
diagnosis to conventional treatment with corticosteroids or EEN in 
newly diagnosed paediatric patients with moderate- to- severe CD. 
Ten weeks after induction therapy, higher clinical remission rates 
are found in the FL- IFX group. Of the FL- IFX- treated patients 
that underwent an endoscopy at week 10, a higher proportion is 
in endoscopic remission than in the conventional treatment group. 
Overall, the proportion of patients in clinical and biochemical 
remission at 1 year did not significantly differ between the two 
treatment groups. However, the trajectory towards remission is 
very different between groups. In particular, FL- IFX treatment 
is superior to conventional treatment in achieving clinical remis-
sion without need for treatment escalation 1 year after the start 
of therapy. Children with moderate- to- severe CD benefit from an 
effective therapy from diagnosis onwards. In this young popula-
tion, delay in achieving remission and frequent flare- ups in the first 
year after diagnosis may slow their pubertal development and affect 
their school attendance and general well- being.21 Moreover, inef-
fective induction treatment strategies in children and adolescents 
put them at risk of developing fistulising or stricturing complica-
tions.9 Findings from the GROWTH Study show that children 
with higher inflammatory markers after induction treatment were 
more at risk of a disease relapse in 18 months and early surgery.22 23 
Similarly, we found in our cohort that inflammatory markers after 
induction treatment were higher in patients needing treatment esca-
lation. Frequent or ongoing corticosteroid use, which is needed in 
42% of the conventionally treated group in our cohort, has debili-
tating side effects and may also affect growth. Our finding, that the 
SDS height- for- age decreases in significantly more conventionally 
treated patients than FL- IFX- treated patients during the first year, 
argues that conventional treatment provides insufficient disease 
control. In addition, steroid- sparing therapy may also result in a 
lower chance of developing disease complications.24 While the 
efficacy of IFX in refractory paediatric patients with CD is well 
established,1 2 this RCT now proves what was suggested in only a 
small number of observational cohort studies in children with CD: 
that FL- IFX therapy results in lower relapse rate and longer dura-
tion of remission than induction with EEN or corticosteroids.5 6 20 25
In our cohort, endoscopic remission rates in FL- IFX- treated 
patients were significantly higher at week 10 than those in 
conventionally treated patients. The endoscopic remission 
rate of 59% in the FL- IFX group is superior to previously 
reported endoscopic remission rates in both paediatric and adult 
studies,26 27 which may be explained by the primary IFX use 
in our study versus the secondary use of IFX in other paedi-
atric studies.28 Clinical and endoscopic remission rates in the 
conventionally treated group are lower than previously shown 
by Borrelli et al.3 This difference may be due to the use of a 
stricter definition of endoscopic remission (SES- CD <3) in our 
cohort and the 2–4 weeks’ longer duration of EEN in the Italian 
cohort. It could suggest that children with moderate- to- severe 
CD may benefit from EEN treatment with a duration of more 
than 6 weeks. The majority of conventionally treated patients 
in our study did not reach clinical remission without the need 
for additional therapies. However, if the 15% of patients in the 
conventional treatment group that did achieve clinical remission 
without treatment escalation would have received FL- IFX, they 
might have been overtreated. As we have so far been unable to 
discriminate these patients on the basis of their clinical profile 
at diagnosis, studies identifying predictors of disease course and 
treatment response are essential.
Since the design of this study in 2015, guidelines were updated 
and the role of therapeutic drug monitoring has increased. In our 
study, reactive TDM was performed based on clinical practice and 
thus the clinician’s decision. In only a few patients this resulted 
in treatment optimisation, as only 2 out of 49 patients received 
interval shortening and/or dose escalation within the first 22 
weeks. Thus far, IFX could be safely restarted in the patients 
in our cohort. However, the risk of increased immunogenicity 
Table 5 Findings at week 52 per treatment group
First- line IFX Conventional P value
wPCDAI, median (IQR) 7.5 (0–15) 10 (0–17.5) 0.476
Clinical remission, n (%) 33/47 (70) 26/46 (57) 0.420
Clinical remission in patients on 
immunomodulator monotherapy, 
n (%)
22/29 (76) 12/18 (67) 0.958
Endoscopic remission, n (%)* 5/18 (28) 5/14 (36) 0.630
SES- CD, median (IQR) 7 (2–7) 6 (0–10) 0.961
Fcal <100 µg/g, n (%) 17/48 (35) 9/47 (19) 0.120
Clinical remission is defined as a wPCDAI <12.5. Endoscopic remission was 
defined as a SES- CD <3. The group of patients on immunomodulator monotherapy 
comprised patients on azathioprine (n=46) and methotrexate (n=1). Baseline 
characteristics of these patients are similar (online supplemental table 2C).
*Eighteen FL- IFX patients and 14 conventionally treated patients consented for 
endoscopy at week 52.
Fcal, faecal calprotectin; IFX, infliximab; SES- CD, Simple Endoscopic Score for 
Crohn’s Disease; wPCDAI, weighted Paediatric Crohn’s Disease Activity Index.
Table 6 Change in SDS height- for- age between baseline and 52 weeks
First- line IFX (n=48) Conventional (n=47) P value
SDS height for age at baseline, median (IQR) −0.07 (−0.84 to 0.76) −0.53 (−1.06 to 0.26) 0.069
SDS height for age at week 52, median (IQR) 0.02 (−0.81 to 0.70) −0.66 (−1.13 to 0.11) 0.021
Change in SDS height- for- age between baseline and 52 weeks 0.08 (−0.05 to 0.21) −0.08 (−0.23 to 0.04) 0.002
Median increase in height (cm) between baseline and 52 weeks 4.0 (1.1–6.2) 2.4 (0.7–5.4) 0.226
IFX, infliximab; SDS, SD score.






Ileocecal resection 1* 2*,* 3
Intra- abdominal abscess 1* 1* 2
Psychosis 1* 0 1
Perianal abscess drainage 0 3*‡‡ 3
Excision of pilonidal cyst 1† 0 1
Hospitalisation 2*,* 3*‡,‡ 5
Total 6 9 15
*One patient treated with IFX and azathioprine.
†One patient treated with azathioprine.
‡One patient treated with prednisolone and azathioprine.
IFX, infliximab;
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and consecutive loss of response after restarting IFX has been 
demonstrated and longer follow- up of our cohort is needed.29 
Based on progressive understanding in clinical practice since the 
design of our study, we do not favour stopping FL- IFX therapy 
after five infusions. However, in adult patients with IBD, the 
concept of cycles of biologics treatment and planned de- escala-
tion is currently being investigated. Reenaers et al demonstrated 
that retreatment with IFX was effective and well- tolerated in a 
group of patients that stopped IFX treatment after at least 1 year 
and 6 additional months of corticosteroid- free remission.30 In 
60% of FL- IFX- treated patients in our cohort, there was no 
need to continue or restart IFX within 6 months after the fifth 
infusion; they continued on AZA monotherapy. Concerns have 
been raised about the use of AZA maintenance therapy, espe-
cially due to the associated risk of lymphoproliferative disor-
ders.31 Although international guidelines and clinical practice 
differ regarding the use of AZA in CD,2 4 this may be a reason 
to continue IFX monotherapy after five infusions instead of 
continuing AZA monotherapy. We cannot draw firm conclusions 
which treatment strategy is most effective and safe as our study 
was not designed to investigate the effectiveness of IFX mono-
therapy versus AZA monotherapy after five IFX infusions.
Counterarguments for implementation of FL- IFX therapy 
could be the increased risk of side effects and higher costs.32 
The overall incidence of adverse events within 1 year was similar 
between both treatment groups, which is in line with findings in 
adults7 and indicates that the use of first- line anti- TNF in these 
patients is safe. The introduction of biosimilars has led to signifi-
cantly decreased costs of IFX treatment.33 In cost- effectiveness 
studies patients received the originator IFX, whereas children in 
our study received the biosimilar CT- P13.32
A clear strength and innovative aspect of this study is the 
inclusion of new- onset and therapy- naïve patients with CD. 
Performing an RCT in children with CD is rarely done and 
extremely challenging. Only 21 patients and their parents 
declined to participate in this trial, which demonstrates the 
patients’ interest in FL- IFX treatment. There are some draw-
backs associated with our study. First, treatment assignment and 
assessments guiding treatment changes were not masked for 
patients and investigators, which could have created a perfor-
mance bias. However, this bias is partly mitigated by the evalua-
tion of growth, faecal calprotectin and endoscopic remission as 
objective outcome measures in this study. Second, while partic-
ipating in the study, not all patients agreed on the endoscopic 
evaluation scheduled in this study at weeks 10 and 52. Based on 
ethical considerations, these patients continued to participate in 
the study, which led to missing endoscopic results. Despite the 
lower numbers, this did not introduce a bias as patients who 
underwent endoscopy had comparable disease characteristics at 
baseline (online supplemental table 2B,C). Third, the difference 
in duration of therapy between FL- IFX (five IFX infusions in 
22 weeks) and conventional treatment (6–8 weeks of EEN or 10 
weeks of prednisolone) may have influenced the interpretation of 
our findings. The duration of conventional treatment, however, 
was in accordance with paediatric CD guidelines and, as such, 
reflects current clinical practice.2 We expect the effect of the 
difference in therapy duration to be minimal, as both groups had 
received AZA monotherapy per protocol for at least 6 months 
at 52 weeks. Although AZA metabolite levels were measured as 
part of clinical care in 74/97 patients and were therapeutic on 
average, we did not incorporate these results in our conclusions 
as data were collected in a non- standardised fashion.
In conclusion, despite the similar clinical remission rates at 1 year 
after diagnosis in both treatment groups, we argue that children 
and adolescents with moderate- to- severe CD would benefit from 
FL- IFX treatment as an insufficiently effective treatment strategy 
impacts their growth and development. Ongoing disease activity or 
corticosteroids use prior to escalation to IFX in the conventional 
treatment group could have been prevented by starting FL- IFX. 
This innovative treatment was well accepted by children and their 
parents, which shows the importance of moving forward with 
protocols to allow us to learn what is best. Future follow- up and 
additional research are needed to determine whether IFX can be 
stopped and for which patients this will be beneficial.
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